Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 11/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 11/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 4/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19997589 | 0.94 | LPL (0.36) | LPLLIPGCSF1RCA1CA2 | |
| SCHEMBL25803846 | 0.92 | SYK (0.44) | LPLLIPGCSF1RCA1CA2 | |
| SCHEMBL15320232 | 0.87 | RORC (0.44) | LPLLIPGCSF1RCA1CA2 | |
| SCHEMBL30717778 | 0.87 | RORC (0.44) | LPLLIPGCSF1RCA1CA2 | |
| SCHEMBL25932163 | 0.87 | PDE4D (0.38) | CSF1RSYK | |
| SCHEMBL16695355 | 0.84 | LPL (0.37) | LPLLIPGCSF1RCA1CA2 | |
| SCHEMBL127954 | 0.84 | PDE4A (0.45) | CSF1R | |
| SCHEMBL129404 | 0.81 | PDE4D (0.41) | LPLLIPGBACE1 | |
| SCHEMBL15969407 | 0.80 | GRM2 (0.38) | LPLLIPGCSF1RCA1CA2 | |
| SCHEMBL740240 | 0.80 | SYK (0.43) | LPLLIPGCSF1RAAK1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2963043-B1 | TETRAHYDROIMIDAZO[1,5-D][1,4]OXAZEPINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| EP-2963043-B1 | TETRAHYDROIMIDAZO[1,5-D][1,4]OXAZEPINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-9458176-B2 | Tetrahydroimidazo(1,5-D)[1,4]oxazepine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-10-04 | — | — | US | disclosed |
| US-9458176-B2 | Tetrahydroimidazo(1,5-D)[1,4]oxazepine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-10-04 | — | — | US | disclosed |
| US-9458176-B2 | Tetrahydroimidazo(1,5-D)[1,4]oxazepine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-10-04 | — | — | US | disclosed |
| EP-2963043-A1 | TETRAHYDROIMIDAZO[1,5-D][1,4]OXAZEPINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2016-01-06 | — | — | EP | disclosed |
| WO-2014133022-A1 | TETRAHYDROIMIDAZO[1,5-D][1,4]OXAZEPINE DERIVATIVE | エーザイ・アール・アンド・ディー・マネジメント株式会社 (JP) | 2014-09-04 | — | — | WO | disclosed |
| US-20140243316-A1 | Tetrahydroimidazo(1,5-D)[1,4]Oxazepine Derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-08-28 | — | — | US | disclosed |
| US-20140243316-A1 | Tetrahydroimidazo(1,5-D)[1,4]Oxazepine Derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-08-28 | — | — | US | disclosed |
| US-20140243316-A1 | Tetrahydroimidazo(1,5-D)[1,4]Oxazepine Derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243316-A1 | Tetrahydroimidazo(1,5-D)[1,4]Oxazepine Derivative | GRM2, GRM1, GRIA2 | LPL 4001/4885LIPG 4467/4885CSF1R 2151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.